TORONTO, June 5, 2013 /CNW/ - Amorfix Life Sciences announced today that
it has completed a second series of studies in a preclinical ovarian
cancer animal model. The Company recently reported positive results of
the first proof of concept study evaluating the ability of their lead
ovarian cancer antibody drug conjugate (ADC) to reduce tumor growth in
a rapidly growing animal model of ovarian cancer. These most recent
data confirm this activity in a second, more slowly growing tumor model
and show a statistically significant inhibition of tumor growth
compared to control animals.
"These are exciting results indicating that our therapeutic antibodies
can specifically deliver a toxic payload directly to tumors resulting
in an inhibition of tumor growth," said Dr. Neil Cashman, Amorfix
co-founder, CSO and Chairman. "Our antibodies are generated against
disease specific epitopes (DSEs) identified with our proprietary
ProMIS™ discovery technology that enable the selective targeting and
killing of tumor cells while sparing normal cells. These proof of
concept studies validate this very innovative approach to therapeutic
intervention and represent a novel path forward for the development of
cancer treatments that are more effective and safer than existing
cancer therapeutic regimens."
"We have made excellent progress with our ovarian cancer program which
demonstrates the value of our business model of identifying good
partners and forming strategic alliances that enable the rapid
development of novel therapeutics," said Dr. Robert Gundel, Amorfix
President and CEO. "We are excited about these most promising results
as ovarian cancer is an area of high unmet medical need and represents
a very large commercial opportunity for the Company."
The Company, in collaboration with Helix BioPharma, is developing this
ADC as a novel treatment for ovarian cancer. The ADC is composed of
antibodies against misfolded prion protein and urease, an enzyme that
acts upon a substrate compound called urea and generates toxic
metabolites that kill tumor cells.
The Company recently announced that exposure of ovarian tumor cells to
paclitaxil, a standard chemotherapeutic agent used for the treatment of
ovarian cancer, resulted in an increased binding of the ADC. These
results suggest that a synergistic killing effect may be generated by
co-administration of chemotherapy drugs and the ADC. The Company is
currently planning these combination studies in animal models of
About the ProMIS Discovery Technology
Amorfix's proprietary drug discovery technology, ProMIS™, is a computer
based algorithm that predicts Disease Specific Epitopes (DSEs), those
regions of proteins most likely to misfold in diseases. Misfolded
proteins are found in numerous diseased cells, including various
cancers and neurodegenerative diseases. The Company uses this
technology to identify DSEs that are only expressed on tumor cells and
not normal cells which enables it to develop antibodies that only bind
to and kill tumor cells without affecting normal cells. Using this
technology, Amorfix has the potential to create antibody therapeutics
that are more efficacious and have a much better safety profile, with
fewer side effects than current cancer therapeutics.
About Ovarian Cancer
Ovarian cancer is the fifth most common cancer among women, and it
causes more deaths than any other type of female reproductive cancer.
Most deaths from ovarian cancer occur in women age 55 and older.
Ovarian cancer is often not diagnosed until late-stage disease when the
cancer has spread to other organs in the body, which contributes to the
short survival time following diagnosis. Ovarian cancer is typically
treated with surgery and chemotherapy. Chemotherapy is not very
effective as a treatment and is associated with a number of potential
dose-limiting side effects due to its non-specific killing of both
tumour and normal cells.
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product
development company developing therapeutic antibodies and diagnostics
targeting misfolded protein diseases. Amorfix utilizes its
computational discovery platform, ProMIS™, to predict novel Disease
Specific Epitopes (DSEs) on the molecular surface of misfolded
proteins. Using this technology, Amorfix is developing novel antibody
therapeutics and companion diagnostics for cancer and amyotrophic
lateral sclerosis (ALS). In addition, Amorfix has developed two
proprietary technologies to specifically identify very low levels of
misfolded proteins in a biological sample: Epitope Protection™ and
AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these
technologies has generated a cerebrospinal fluid (CSF) screening test
for both Alzheimer's disease (AD) and mild cognitive impairment (MCI),
and an ultrasensitive method for detecting the hallmark of AD,
aggregated beta-Amyloid, in brain tissue, CSF and blood from animal
models of AD. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release. This information release may
contain certain forward-looking information. Such information involves
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements
should not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs
as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by the Company in its
public securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life
SOURCE: Amorfix Life Sciences Ltd.
For further information:
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 644-7358
Fax: (416) 847-6899